Skip links

GSS EU Science Funding Gateway

Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers

HORIZON-MISS-2027-02-CANCER-02
Forthcoming
General information
ProgrammeHorizon Europe (HORIZON)
Programme divisionHorizon Europe Framework Programme (HORIZON); Global Challenges and European Industrial Competitiveness; Health
CallHORIZON-MISS-2027-02 (Supporting the implementation of the Cancer Mission)
Type of actionHORIZON-IA HORIZON Innovation Actions
Type of MGAHORIZON Lump Sum Grant
Deadline modelsingle-stage
Planned opening date10 February 2027
Deadline date16 September 2027
StatusForthcoming
OECD fieldsClinical medicine
EC cross-cutting prioritiesDigital Agenda, Artificial Intelligence
Cluster or programme partEU Missions (HORIZON-MISS)
Thematic communities (as in the COST Action Graph)Cancer, Open science and FAIR data
Beneficiary categories (GSS model, in training)Associations, Businesses, Legal Entities, Researchers/Research Centers/Institutions, Small and Medium Enterprises (SMEs)
Topic description

Expected Outcome:

Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes:

  • Patients afflicted by lung, bowel, breast or prostate cancer[1], will benefit from the outcomes of evidence-based, tailored, innovative, affordable and accessible diagnosis- and treatment-centred clinical research programmes by comprehensive cancer infrastructures[2].
  • Researchers, physicians, patient representatives, civil society, charities, foundations, insurance companies, SMEs and innovators[3] will seize opportunities to respectively co-create, support, upscale or commercialise outcomes of evidence-based, tailored, affordable and accessible clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer.
  • National and regional healthcare providers, healthcare payers, policymakers and authorities in European regions, EU Member States and Associated Countries have the evidence to engage in piloting, upscaling or implementing appropriate clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer.

Scope:

Lung, bowel, breast and prostate cancer incidence, mortality and prevalence across EU Member States and Associated Countries are increasing while showing substantial variation, with Central and Eastern European communities, regions and countries particularly affected[4]. At the same time, the level of development of comprehensive cancer infrastructures continues to vary considerably across EU Member States and Associated Countries, contributing to inequalities, in particular in terms of clinical research capacity as well as quality of and access to innovative diagnostic and therapeutic interventions.

Applicants should address all of the following:

  • Comprehensive cancer infrastructures across the EU Member States and Associated Countries come together to conduct clinical research on lung, bowel, breast or prostate cancer focusing on at least one of the following areas:
    • Innovative diagnostics;
    • Radiotherapy, surgery, chemotherapy;
    • Therapeutic cancer vaccines for the treatment of cancer patients with early-stage, advanced, metastatic or minimal residual disease (e.g. after debulking by surgery, chemotherapy, radiotherapy, or immunotherapy);
    • Implementation of appropriate clinical practice guidelines for diagnosis and treatment in countries without or with limited Comprehensive Cancer Infrastructures;
  • Comprehensive cancer infrastructures should extensively pilot and upscale innovative diagnostic or treatment programmes in at least four different EU Member States or Associated Countries. One of the four targeted EU Member States or Associated Countries should represent a country without or with a less developed comprehensive cancer infrastructure.
  • To ensure that together they address - and whenever feasible - overcome challenges because of the national, regional, or local research and healthcare context (e.g. those faced by small(er) EU Member States, or due to a large rural population, or particular cancer burden, socio-economic or environmental situation, or limited clinical research capacity[5]), when designing and conducting innovative clinical research programmes with added value for the timely diagnosis and treatment of patients with lung, bowel, breast or prostate cancer;
  • Identify additional resources through the European Regional Development Fund (ERDF), the Technical Support Instrument[6], the Resilience and Recovery Facility (RRF), philanthropy, the European Investment Bank Group (EIB[7], EIF[8]) or any other initiative;
  • Innovative clinical research programmes should be defined together with patients and their caregivers/families using participative research models and adapted to the needs of the target population and the specificities of healthcare provision at local, regional, or national level, duly reflecting the (cultural) diversity and available resources across EU Member States and Associated Countries;
  • Data should be disaggregated by sex, gender, age and other relevant variables, such as by measures of socio-economic status or ethnicity;
  • All datasets produced should be described with metadata records in the EU dataset catalogue of the European Health Data Space, while all tools and models should take advantage of current European research infrastructures, should follow the principles of open science and made available through the future UNCAN.eu platform;
  • Applicants should include an appropriate mix of stakeholders from various disciplines and sectors[9] and provide details of the clinical study(ies) in the dedicated annex using the template provided in the submission system.

Successful proposals will be asked to join the 'Diagnosis and treatment” cluster[10] for the EU Cancer Mission and should include a budget for networking, attendance at meetings, and joint activities[11]. The Commission will facilitate coordination of these activities.

The successful proposals are expected to build on relevant networks launched under the Europe’s Beating Cancer Plan that could facilitate cross-border clinical trials[12], resources made available by relevant ESFRI Research Infrastructures[13], and the Knowledge Centre on Cancer (KCC) to foster EU alignment and coordination[14].

[1] Any age group or cancer subtype

[2] National or regional infrastructures that provide resources and services to support, improve and integrate cancer care, research, training of care professionals and education for cancer patients, survivors and their families/carers of any age group. Hence, comprehensive cancer infrastructures could consist of any combination, number or type of -public or private- cancer centre, hospital, university medical centre, research department or institute, company, public health facility, etc.

[3] Innovators turn research results into new and better services and products, to remain competitive in a global marketplace and to improve the quality of life of Europe’s citizens.

[4] Cancer inequalities registry: https://cancer-inequalities.jrc.ec.europa.eu/

[5] research laboratories, diagnostics and clinical trial infrastructures

[6] Technical Support Instrument (TSI), DG REFORM

[7] Homepage | European Investment Bank

[8] eif.org/index.htm

[9] such as physicians, academia, patients and their caregivers, patient representatives, engineers, behavioural scientists, SMEs, business networks, insurance companies, charities and foundations, research organisations, civil society.

[10] In order to address the objectives of the EU Cancer Mission, participants will collaborate in project clusters to leverage EU-funding, increase networking across sectors and disciplines, and establish a portfolio of EU Cancer Mission R&I and policy actions.

[11] Examples of those activities are research or research capacity, organising joint workshops, establishing best practices, joint communication or citizen engagement activities with projects funded under other clusters and pillars of Horizon Europe, or other EU programmes, as appropriate. Proposals are not required to include details of these activities, as they will be defined during the grant agreement preparation and during the life of the project.

[12] Such as the EU Network of comprehensive cancer centres EUNetCCC

[13] Such as BBMRI, EATRIS, ELIXIR, ECRIN.

[14] Hosted by the European Commission's Joint Research Centre (JRC). Especially through the ’European Guidelines and Quality Assurance Schemes for Breast, Colorectal and Cervical Cancer Screening and Diagnosis‘, and the ’European Cancer Information System (ECIS)’ and the ’European Cancer Inequalities Registry (ECIR), see https://knowledge4policy.ec.europa.eu/cancer_en.

Topic conditions and documents
">

General conditions

1. Admissibility conditions: Proposal page limit and layout

described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.

Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.

2. Eligible countries

described in Annex B of the Work Programme General Annexes.

A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.

3. Other Eligibility Conditions

described in Annex B of the Work Programme General Annexes.

4. Financial and operational capacity and exclusion

described in Annex C of the Work Programme General Annexes.

5a. Evaluation and award: Award criteria, scoring and thresholds

described in Annex D of the Work Programme General Annexes.

5b. Evaluation and award: Submission and evaluation processes

The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold is 12.

described in Annex F of the Work Programme General Annexes and the Online Manual.

5c. Evaluation and award: Indicative timeline for evaluation and grant agreement

described in Annex F of the Work Programme General Annexes.

6. Legal and financial set-up of the grants

Eligible costs will take the form of a lump sum as defined in the Decision of 7 July 2021 authorising the use of lump sum contributions under the Horizon Europe Programme – the Framework Programme for Research and Innovation (2021-2027) – and in actions under the Research and Training Programme of the European Atomic Energy Community (2021-2025) [[This decision is available on the Funding and Tenders Portal, in the reference documents section for Horizon Europe, under ‘Simplified costs decisions’ or through this link: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/ls-decision_he_en.pdf]].

The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.

described in Annex G of the Work Programme General Annexes.

Specific conditions

described in the specific topic of the Work Programme

Budget overview
Topic and type of actionBudget 2027 (EUR)StagesOpening dateDeadlineContributions (EUR)Indicative number of grants
HORIZON-MISS-2027-02-CANCER-03 - HORIZON-RIA HORIZON Research and Innovation Actions24 000 000single-stage10 February 202716 September 20277 000 000 to 9 000 0003
HORIZON-MISS-2027-02-CANCER-02 - HORIZON-IA HORIZON Innovation Actions20 000 000single-stage10 February 202716 September 20277 000 000 to 10 000 0003
HORIZON-MISS-2027-02-CANCER-06 - HORIZON-CSA HORIZON Coordination and Support Actions3 000 000single-stage10 February 202716 September 20273 000 0001
HORIZON-MISS-2027-02-CANCER-01 - HORIZON-RIA HORIZON Research and Innovation Actions32 323 812single-stage10 February 202716 September 20277 000 000 to 8 000 0004
HORIZON-MISS-2027-02-CANCER-05 - HORIZON-PCP HORIZON Pre-commercial Procurement26 000 000single-stage10 February 202716 September 20278 000 000 to 10 000 0003
HORIZON-MISS-2027-02-CANCER-04 - HORIZON-RIA HORIZON Research and Innovation Actions10 000 000single-stage10 February 202716 September 20275 000 000 to 7 000 0003
Partner search
On the EU Funding & Tenders portal

The portal lists the partner search announcements published for this topic: open the topic on the portal and go to "Partner search announcements".

Through the GSS community

No requests yet for this call.

Post a partner request for this call

Topic Q&As

Questions and answers published by the EC for this topic are on the portal: open the topic on the portal and go to "Topic Q&As".

Get support

Online Manual is your guide on the procedures from proposal submission to managing your grant.

Horizon Europe Programme Guide contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.

Funding & Tenders Portal FAQ – find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.

Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.

National Contact Points (NCPs) – get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (‘third-countries’).

Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.

IT Helpdesk – contact the Funding & Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.

European IPR Helpdesk assists you on intellectual property issues.

CEN-CENELEC Research Helpdesk and ETSI Research Helpdesk – the European Standards Organisations advise you how to tackle standardisation in your project proposal.

The European Charter for Researchers and the Code of Conduct for their recruitment – consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.

Partner Search help you find a partner organisation for your proposal.

Keywords

Keywords

Anticancer therapyClinical medicineDigital dataGender in basic medicinePersonalised medicineRadiologynuclear medicine and medical imagingTranslational medicine
Source

Content published by the European Commission on the EU Funding & Tenders portal, updated automatically.

This website uses cookies to improve your web experience.
Home
Account
Cart
Search
Explore
Drag